IL-17–driven transcriptional programs in muscle fibroblasts are not required for pathogenesis in murine anti-histidyl-tRNA synthetase (Jo-1) myositis Authors: Decheng Li, Daniel P Reay, Yang Li, Shachi P Vyas, Kenta Yamamoto, Dana P Ascherman, Sarah L Gaffen Published: 2026 ABSTRACT AbstractIdiopathic inflammatory myopathy (IIM) is a systemic autoimmune disease targeting muscle and extramuscular organs, but the molecular mechanisms driving IIM pathogenesis remain largely undefined. Muscle fibroblasts are central to orchestrating inflammation in myositis. Here, we investigated muscle fibroblast dynamics using a single-cell RNA sequencing approach in an established murine model of anti-histidyl–tRNA synthetase (HRS, also known as Jo-1)-induced myositis. In fibroblasts, there was a robust activation of an IL-17 gene signature during disease. Among the induced genes was Nfkbiz, which encodes IκBζ, a noncanonical NF-κB transcriptional coactivator known to be key for pathologic IL-17 signaling in a variety of autoimmune settings. In muscle fibroblasts, IκBζ was potently activated by IL-17 in vitro and was essential for IL-17 signaling responsiveness. Surprisingly, however, the IL-17–IκBζ signaling axis was dispensable for the histopathological phenotype in HRS-induced myositis. Thus, despite a prominent IL-17 transcriptional signature, IL-17 and IκBζ are not required for autoantibody production or tissue inflammation in this model system.Keywords: cytokine signaling, idiopathic inflammatory myopathy, IL-17, IκBζ, Th17 Introduction Idiopathic inflammatory myopathy (IIM) comprises a heterogeneous group of systemic autoimmune disorders characterized by chronic muscle inflammation, typically with additional involvement of extramuscular organs such as the skin, joints, and lungs.1–3 IIM subsets are associated with characteristic autoantibody profiles and distinct clinical presentations, including the anti-synthetase syndrome (ASyS) that is marked by arthritis, Raynaud’s phenomenon, “mechanic’s hands,” fever, and interstitial lung disease.4 Among the autoantibodies identified in patients with IIM, anti-synthetase autoantibodies are particularly prevalent and are linked to disease phenotype.5,6 However, because of critical gaps in our understanding of disease pathogenesis, current therapeutic strategies are mostly limited to nonspecific global immunosuppression, primarily corticosteroids.7 These conventional therapies are usually inadequate and can be associated with infection and other severe side effects, highlighting a need for disease models to elucidate relevant disease pathways and establish more rational therapeutic strategies. Compared with many autoimmune conditions, relatively little is known about the underlying pathogenic mechanisms of IIM. Here, we took advantage of an established murine model of myositis in which immunization with the histidyl-tRNA synthetase autoantigen (HRS; often called Jo-1) recapitulates many phenotypic features of the ASyS, including muscle inflammation, autoantibody production, and activation of Ag-specific T cells.8 The bridge between initial immune activation to sustained muscle pathology is not well understood, though recent studies have demonstrated a crucial interplay among fibroblasts, macrophages, and T cells in initiating the autoimmune response and potentiating disease progression.9 From the perspective of immune signaling, TLR pathways and MyD88, the shared adaptor of the TLR family, are essential for induction of HRS-myositis.6 Surprisingly, despite close parallels to TLRs in terms of signaling mechanisms, IL-1R signaling is dispensable for disease development.9 Apart from MyD88, other downstream effectors driving murine myositis remain undefined. IL-17 has gained attention in directing pathogenesis of various autoimmune diseases that include psoriasis,10 psoriatic and rheumatoid arthritis,11 multiple sclerosis,12 and ankylosing spondylitis.13 In addition to these disorders, IL-17 is elevated in serum of patients with IIM and ASyS,14 dermatomyositis, and polymyositis.15 Gene profiling from clinical studies indicates IL-17 pathways are upregulated in IIM, and serum IL-17 levels correlate positively with disease severity.14–16 However, though IL-17 is structurally related to the TLR/IL-1R families17,18 and activates many shared downstream signaling cascades,19,20 little is known about its potential role in IIM pathogenesis at a molecular level. IL-17 is produced by lymphocytes but exerts signaling effects on nonhematopoietic cells, particularly mesenchymal cell types, including fibroblast reticular cells, synovial fibroblasts, adipocytes, and myoblasts.21–24 IL-17 receptor A (IL-17RA) and IL-17RC engage a multifunctional adaptor protein Act1, which activates or induces transcriptional and posttranscriptional signaling effectors. Transcription factors induced by IL-17 include canonical NF-κB as well as the coactivator IκBζ (NF-κB inhibitor ζ; Nfkbiz), CCAAT/enhancer binding proteins (C/EBPs), AT-rich interacting protein 5a (Arid5a), and MAPK-associated transcription factors (c-Fos and c-Jun).20,25 These signals promote upregulation of inflammatory cytokines, chemokines, metabolic genes, tissue repair genes, and antimicrobial proteins, all of which characterize the IL-17 signature response.26 IκBζ is an atypical member of the IκB family that functions primarily as an activator of target genes, though repressor function has also been documented.27–30 Mice with a global Nfkbiz deficiency are resistant to IL-17–driven autoimmune disease models such as imiquimod dermatitis31 and experimental autoimmune encephalomyelitis.32 Loss of IκBζ also promotes high susceptibility to IL-17–dependent fungal infections caused by Candida albicans.33 Thus, IκBζ is considered a central mediator of the IL-17 pathway in vivo, though the full extent of its activities is not known. In this study, we interrogated the IL-17/IκBζ signaling axis in an established model of HRS-induced myositis,8,34 premised on existing data in the literature correlating IL-17–associated pathways in disease pathogenesis.35–37 High-titer anti-HRS Abs are found in humans with the ASyS, and immunization of mice with recombinant HRS recapitulates many hallmarks of disease in this model system.6,38 Transcriptome-wide analysis by bulk and single-cell RNA sequencing (scRNA-seq) revealed marked activation of the IL-17 pathway in inflamed muscle of HRS-induced myositis, particularly within the fibroblast population. Muscle fibroblasts in vitro exhibited robust IL-17–dependent IκBζ activation, and expression of genes downstream of IL-17 signaling required IκBζ. Contrary to expectations, IL-17 signaling through Act1 or IκBζ was not required for manifestations of HRS-induced myositis, including generation of autoantibodies or immune cell infiltration of muscle. Collectively, these findings suggest the involvement of multiple, potentially redundant immune pathways in the pathogenesis of IIM. Materials and methods Recombinant Ag The immunodominant N-terminal fragment of murine HRS (residues 1–151) was expressed as a fusion protein with maltose-binding protein (MBP) and designated as MA/MBP.8 MA/MBP was expressed in Escherichia coli, purified with amylose resin (New England Biolabs, Ipswich, MA), and dialyzed in PBS, as previously described.39 Filter-sterilized recombinant MA/MBP was administered by i.m. injection. Mice Mice were on the C57BL/6 background and housed in specific pathogen–free conditions. Act1−/− were from the National Institutes of Health.40Nfkbizfl/fl (RIKEN, RBRC06410)41 were crossed to Rosa26CreERT2 (Jackson Laboratory, 011694). If noted, mice were given tamoxifen (TAM) (20 mg/mL in sesame or corn oil) i.p. for gene deletion for 5 d, then rested for 7 to 9 d.33 Experiments were conducted according to national and international guidelines and approved by the University of Pittsburgh Institutional Animal Care and Use Committee. HRS-induced myositis and histopathology To induce myositis, 100 µL of affinity-purified, filter-sterilized recombinant HRS (3–5 mg/mL) was administered by bilateral hamstring injection (50 µL/side) in female mice 8 to 10 wk old. On day 18 after immunization, muscle tissue, serum, and draining lymph nodes (LNs) were collected. Hamstring was fixed in 10% formalin, paraffin-embedded, and stained with H&E. Images were acquired on an EVOS FL imaging system and processed without cropping or alteration of brightness and contrast. Myositis severity was determined by histopathology scoring on a defined 0 to 3 scale that reflects the intensity and distribution of inflammatory infiltrates, as previously described.9 Scoring was performed by 2 individuals in a blinded manner, and histology scores were averaged. Bulk RNA-seq and data processing Bulk RNA-seq was performed on frozen mouse hamstrings (n = 9 controls and 7 HRS treated). Libraries were prepared using the NEBNext Poly(A) mRNA Magnetic Isolation Module and the NEBNext Ultra II Directional RNA Library Prep Kit for Illumina (New England BioLabs, E7760). Libraries were sequenced on an Illumina NovaSeq 6000, NovaSeq X Plus, and NextSeq 2000 platforms. Bulk RNA-seq data were aligned to GRCmm39 by STAR (version 2.7.8a) and normalized by trimmed mean of M-values. Differential analysis was conducted using the voom function in the limma package. Single-cell RNA-seq analysis scRNA-seq data from HRS-induced myositis muscle infiltrates were from our published datasets (Gene Expression Omnibus accession GSE 229059), consisting of 3 control and 3 HRS-immunized groups. Each group contain 3 to 5 mice. Data were analyzed in R using the Seurat package (version 5.3.0). To remove doublets and low-quality data, cells with more than 5,000 or fewer than 200 detected genes were removed. Cells with a high percentage of mitochondria genes were eliminated. Raw counts were normalized using the NormalizeData function. Batch effects were corrected for using canonical correlation analysis using the IntegrateLayers function. Cell-interaction analysis Cell-cell communication signals were assessed by the CellChat package (version 1.6.1). NetVisual_circle function was used to evaluate signaling strength and number of interactions among cell clusters. Interaction strength represents communication probabilities derived from a mass action model incorporating ligand and receptor expression. Flow cytometry Muscle tissue was isolated from control or HRS-immunized mice and digested with GentleMACS Skeletal Muscle Dissociation Kit (Miltenyi Biotec, 130-098-305) to obtain single cells. Samples were incubated in 50 ng/mL PMA and 1 µM ionomycin (Sigma-Aldrich), and GolgiPlug (1:1,000 dilution) for 4 h at 37 °C. Cells were stained with Fixable Viability Dye eFluor506 (Invitrogen, 65-0866-14). Samples were pre-incubated with anti-CD16/CD32 mAb (clone 93; Invitrogen, 14-0161-82) then stained for the following receptors: CD45.2 (BV786, clone 104; BD, 563686); CD11b (PerCP-Cy5.5, clone M1/70; BD, 550993); CD3 (BV711, clone 17A2; Biolegend, 100241); CD4 (BUV395, clone RM4-5; BD, 568375); and CD8α (PE-Cy5, clone 53-6.7; Biolegend, 100709) for 30 min at 4 °C. For intranuclear staining, samples were fixed and permeabilized with Foxp3/Transcription Factor Staining Buffer Set (Invitrogen, 00-5523-00), then stained for the following: Tbet (PE, clone 4B10; Invitrogen, 12-5825-82); GATA3 (PE-CF594, clone L50-823; BD, 563510); RORγt (PE-Cy7, clone B2D; Invitrogen, 25-6981-82); and Foxp3 (eFluor450, clone FJK-16s; Invitrogen, 48-5773-80). Data were acquired on an Aurora spectral flow cytometer (Cytek Biosciences) and analyzed using FlowJo (v10.10; BD Biosciences). Cell culture and cytokines Hamstring muscle was digested with Skeletal Muscle Dissociation Kit (Miltenyi Biotec, 130-098-305) and was dissociated using GentleMACS (Miltenyi Biotec) M-tubes, and filtered in a 70-μm cell strainer. Cells were cultured in DMEM (Gibco) with 10% FBS and antibiotics. Fibroblast stimulation experiments were performed during passages 3 to 5. Mouse IL-17 (PeproTech) was used at the indicated concentrations, and recombinant HRS was used at 20 μg/mL for stimulation. RNA silencing and quantitative PCR ON-TARGET plus SMARTpool small interfering RNA (siRNA) targeting Nfkbiz (Dharmacon, L-013497-00-0005). Fibroblasts were seeded overnight in antibiotic-free medium and transfected 18 to 24 h later with 50 nM siRNA in DharmaFect Reagent. Culture medium was replaced after 24 h and cells stimulated 24 h later. RNA isolation and DNA synthesis were conducted using RNeasy Mini Kits (Qiagen) and iScript cDNA Synthesis Kits (Bio-Rad). Quantitative PCR (qPCR) was performed with the SYBR Green FastMix ROX (Quanta Bioscience) on a CFX96 Real-Time PCR detection system (Bio-Rad). Relative expression was calculated by normalizing to Gapdh. Primers were from QuantiTect Primer Assays (Qiagen). Immunoblotting Denaturing SDS-PAGE was performed as described previously.42,43 The following Abs were used for immunoblotting: anti-IκBζ (Cell Signaling, 93726S), anti–β-actin (Abcam, ab49900), anti-YY1 (Santa Cruz Biotechnology, sc1703), and anti–α-tubulin (Abcam, ab40742). Blots were visualized with a FluorChem E imager (ProteinSimple). ELISA We coated 96-well flat-bottom polystyrene microplates (Corning) with recombinant murine HRS (1.0 µg/mL) in carbonate buffer (50 mM NaHCO3/Na2CO3, pH 9.6) overnight at 4°C. Diluted serum (1:500) was added for 2 h. HRP-conjugated anti-mouse IgG Abs (Santa Cruz Biotechnology, sc525-409), anti-IgG1 (SouthernBiotech, 5300-0513), anti-IgG2a (SouthernBiotech, 1081-05), and anti-IgM (Abcam, ab97230) were used to detect serum Abs. Enzymatic reactions were visualized using tetramethylbenzidine (R&D Systems, DY999) and terminated with 1 N H2SO4 (R&D Systems, DY994). Color development was measured at 450 and 540 nm. Statistical analysis Data were analyzed by GraphPad Prism. Serum Abs, histology scores, and qPCR were analyzed by 1-way ANOVA with Tukey’s and Dunnett’s multiple comparisons test. scRNA-seq data were analyzed by Student’s t test. Two-tailed P < 0.05 were considered significant. In depicted results, each symbol represents 1 mouse or sample, and P values are reported in the figures or figure legends. Results IL-17 signaling is activated in HRS-induced myositis To investigate the immunoregulatory role of the IL-17 pathway in myositis, we assessed the impact of Act1, the essential IL-17R–associated adaptor, and the IL-17–associated transcription factor IκBζ in a murine model of HRS myositis. To that end, mice were immunized with recombinant murine HRS in the hamstring muscle, triggering immune infiltration in a perimysial and endomysial distribution that resembles human pathology (Fig. 1A). Myositis severity was determined by histopathology scoring on a defined 0 to 3 scale that reflects the intensity and distribution of inflammatory infiltrates (see Materials and Methods). Bulk RNA-seq of muscle 18 d after immunization showed enrichment of a characteristic IL-17 signature gene profile, including Cebpb, Cebpd, Zc3h12a, Arid5a, Lcn2, Ccl2, Cxcl1, and Il619 (Fig. 1B, C and Fig. S1A). Genes encoding IL-17 receptor subunits (Il17ra, Il17rc) were also upregulated (Fig. 1B, C), likely reflecting expansion of both immune and nonimmune cells that express these receptors. An IL-17 signaling gene signature is upregulated in HRS-induced myositis. (A) Workflow of murine myositis model. (B) IL-17 signature genes in murine muscle bulk RNA-seq, comparing mice with HRS/Jo-1–induced myositis (n = 7) to PBS-treated controls (n = 9), visualized in the heat map. (C) Volcano plot of differentially expressed genes in HRS-induced myositis compared with PBS-treated controls. Genes with log2 fold change (FC) > 1 and adjusted P < 0.05 are designated as upregulated; those with a log2 FC < –1 and adjusted P < 0.05 are designated as downregulated. (D) Gene Ontology (GO) pathway enrichment comparing controls and HRS-induced myositis, as analyzed by Wilcoxon rank-sum test. (E) Gene set enrichment analysis for the IL-17 signaling pathway as identified by GO. (F) Heat map of MAPK signaling genes in muscle by bulk RNA-seq, comparing HRS-induced myositis (n = 7) and PBS-treated controls (n = 9). (G) Representative plots of Tbet+ and RORγt+ in CD4+ T cells in muscle infiltrates. Percentages of viable CD11b−, CD3+, CD4+, CD8a− Tbet+/GATA3+/RORγt+/Foxp3+ T cells in total CD45+ cells and their cell counts are shown, analyzed by unpaired 2-tailed t test. Each symbol represents 1 mouse. *P < 0.05. Corresponding Gene Ontology analyses showed enrichment of pathways include cytokine–cytokine receptor interactions, IL-17, NF-κB, and TLR signaling pathways, and Th17 differentiation (Fig. 1D). Further supporting the involvement of the Th17 axis, gene set enrichment analysis analyses indicated significant upregulation of the IL-17 signaling pathway in HRS versus control samples (Fig. 1E). In addition to NF-κB profiles, we also saw upregulation of signature genes of the MAPK signaling pathway during muscle inflammation (Fig. 1F). Flow cytometry of muscle cells showed increases in percentages and/or cell counts of Th17 cells (RORγt+), Treg (Foxp3+), and Th1 (Tbet+) cells (Fig. 1G, and Fig. S2A, B). Collectively, these data were suggestive of an association between the type 17 pathway and pathogenesis of HRS-induced myositis. Muscle fibroblasts exhibit IL-17 signatures in HRS-induced myositis To understand the function and role(s) of different cell types activated during myositis, we performed scRNA-seq in dissociated muscle tissue 18 d after immunization (PBS controls vs HRS-injected). We focused on fibroblasts based on their demonstrated roles in coordinating key pro-inflammatory interactions between macrophages and T cells in HRS-induced myositis.9 Single-cell analysis revealed 6 distinct fibroblast subclusters derived from a total of 5,400 cells (Fig. 2A, B, and Figs. S1B, Fig S3). Pi16+ inflammatory fibroblasts were characterized by high expression of Il18 and Il33 indicative of immune-regulating function, consistent with reports regarding a role in immune activation and leukocyte recruitment44–46 (Fig. S1C). Ccl19+ fibroblasts were associated with robust expression of Igfbp3, Saa3, and Apoe, reflecting their role in metabolism and regulation of inflammation, including T- and dendritic cell–recruitment to local tissues.47 We also identified Cxcl14+ fibroblasts that likely facilitate tissue homeostasis and structural support,48 as well as a stress-responsive population defined by long noncoding RNAs Malat1 and Neat1 indicative of an inflammatory cellular stress signature.49,50 Lastly, a cycling population of proliferating fibroblasts was identified by genes including (but not limited to) Kif4 and Kif18b51 (Fig. S1A). Gene expression in muscle fibroblasts in HRS-induced myositis. (A) Workflow of scRNA-seq in murine muscle. Cells from muscle were isolated 18 d after immunization, comparing PBS-injected controls and HRS/Jo-1 immunized mice. (B) Uniform Manifold Approximation and Projection (UMAP) analysis showing subclusters of the following muscle fibroblasts: Pi16+ inflammatory fibroblasts, Ccl19+ inflammatory fibroblasts, Cxcl14+ homeostatic fibroblasts, Col8a1+ myofibroblasts, Malat1+ stress-responsive fibroblasts, and Kif4+ proliferating fibroblasts. (C) Percentage of fibroblast subclusters in control vs HRS-induced myositis. Colors correspond to the key depicted in (B). (D and E) Interaction strength (D) and numbers of interactions (E) between muscle cell clusters. Interaction strength represents ligand-receptor–mediated intercellular communication probability, determined by CellChat. (F) Kyoto Encyclopedia of Genes and Genomes pathway enrichment in muscle fibroblasts from control vs HRS-immunized mice. (G) Expression of IL-17R subunit mRNA (Il17ra, Il17rc) in control vs HRS-immunized muscle, analyzed by Wilcoxon rank-sum test. (H and I) Expression of Nfkbiz, Cebpb, and Cebpd in indicated clusters in control vs HRS muscle tissue, analyzed by Wilcoxon rank-sum test. B/Plasma, blood or plasma cells; FDR, false discovery rate. Additional analysis indicated that fibroblast subsets expanded differentially in HRS-induced myositis compared with controls (Fig. S1B). While the Pi16+ inflammatory subset increased, the Cxcl14+ homeostatic subset decreased (Fig. 2C), likely reflecting transition to an inflammatory state. The increased proportion of proliferating fibroblasts in HRS-induced myositis further indicated a state of activation driven by the inflammatory milieu. Analysis of cell–cell interactions between fibroblast and other cell types through CellChat predicted robust communications from fibroblasts to T-cell, NK cell, neutrophil, and macrophage and dendritic cell populations within the muscle infiltrates (Fig. 2D, E). Consistent with these observations and in agreement with the bulk RNA-seq data (Fig. 1D), many cytokine and chemokine pathways that mediate cell–cell interactions were enriched in fibroblasts after induction of myositis (Fig. 2G). Enrichment of Th17 differentiation pathways and IL-17 signaling were similarly identified by Kyoto Encyclopedia of Genes and Genomes analysis. In addition to upregulation of genes encoding IL-17R subunits (namely, Il17ra and IL17rc) (Fig. 2F), the transcriptional cofactor Nfkbiz, encoding IκBζ, was upregulated in muscle fibroblasts in HRS-induced myositis (Fig. 2H). In contrast, other known IL-17–inducible transcription factors such as C/EBP family members (Cebpb, Cebpd)52 were downregulated in fibroblasts during inflammation (Fig. 2I, J). IL-17 upregulates IκBζ in muscle fibroblasts Because fibroblasts represent a key cell compartment in myositis,9,53 we assessed the IL-17–IκBζ pathway in primary murine muscle fibroblasts. Nfkbiz (IκBζ) expression was elevated after HRS stimulation of muscle fibroblasts (Fig. 3A).6 Primary muscle fibroblasts treated with IL-17 also exhibited a rapid and robust upregulation of Nfkbiz mRNA, detectable as early as 0.5 h, followed by induction of IκBζ protein at 1.5 h (Fig. 3B, C, and Fig. S4A, B). Expression was sustained for at least 9 h, with some evidence of waning at this time point (Fig. 3B, C). Although IκBζ is a transcription coactivator functioning mainly in the nucleus, both cytoplasmic and nuclear fractions had high levels of IκBζ after IL-17 stimulation (Fig. 3D). Thus, primary muscle fibroblasts are highly sensitive to IL-17, with potent induction of IκBζ. IL-17 induces IκBζ in primary muscle fibroblasts. (A) Primary muscle fibroblasts from WT mice were treated with HRS (20 μg/mL) and Nfkbiz was assessed by qPCR normalized to Gapdh (n = 3–4). Data are reported as mean ± SEM and were analyzed by 1-way ANOVA with Tukey’s test for multiple comparisons. (B) Muscle fibroblasts were stimulated with IL-17 (100 ng/mL) for the indicated times. Expression of Nfkbiz was assessed by qPCR, normalized to Gapdh. Data are reported as mean ± SEM and were analyzed by 1-way ANOVA with Dunnett’s test for multiple comparisons. (C and D) Muscle fibroblasts were treated with IL-17 for the indicated time points (C), and whole-cell lysates were analyzed by immunoblotting for IκBζ, a nuclear loading control YY1, and a cytoplasmic loading control α-tubulin. Data representative of 3 independent experiments. (D) Muscle fibroblasts were stimulated with IL-17 at 100 ng/mL for 3 h. Nuclear and cytoplasmic lysates were analyzed by immunoblotting. Data representative of 3 independent experiments. **P < 0.01, ****P < 0.0001. We used RNA silencing to assess the requirement for IκBζ in IL-17 signaling and downstream gene expression in primary muscle fibroblasts. As shown, Nfkbiz silencing was highly efficient at both the mRNA and protein levels (Fig. 4A, B). Knockdown of Nfkbiz significantly reduced IL-17–inducible expression of many inflammation-associated genes such as Lcn2 and Il6 (Fig. 4C). However, not all genes were equally affected, because Ccl2 was only modestly suppressed in the absence of Nfkbiz (Fig. 4C). Thus, IκBζ mediates IL-17–dependent gene expression in muscle fibroblasts, with some variability depending on the gene target. IκBζ regulates IL-17 signaling in muscle cells. (A) Primary muscle fibroblasts were transfected with the indicated siRNAs and, 48 h later, were treated with or without IL-17 for 3 h. Un, untreated. Expression of Nfkbiz was analyzed by qPCR, normalized to Gapdh. (B) Cell lysates from (A) were analyzed by immunoblotting for IκBζ or β-actin. The depicted image is representative of 3 independent experiments. (C) Expression of Lcn2, Il6, and Ccl2 in lysates from (A), normalized to Gapdh. Data are reported as mean ± SEM and were analyzed by 1-way ANOVA with Tukey’s test for multiple comparisons. *P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001. IL-17 signaling and IκBζ are dispensable for HRS-induced myositis Together, these findings suggested the possibility that IL-17 signaling through IκBζ was likely to contribute to pathology in myositis. To test this hypothesis, we evaluated the severity of HRS-induced myositis in mice lacking the central IL-17 signaling adaptor, Act1 (Act1−/−). Mice with a germline Nfkbiz deletion exhibit early-onset autoinflammatory signs sometimes likened to Sjogren’s syndrome,41,54 so to bypass these confounding issues, we created mice that have a constitutive but TAM-inducible conditional allele (NfkbizR26ERT2).40Act1−/−, Nfkbizfl/fl (wild-type [WT] equivalent), and NfkbizR26ERT2 (Nfkbiz-deficient) mice were treated with TAM and immunized with recombinant HRS, and we assessed disease parameters after 18 d (Fig. 5A). We saw similar expansion of para-aortic LNs in all immunized mice (Fig. 5B), indicative of successful immunization. Although autoantibody production is not the direct cause of muscle inflammation in myositis,55 the presence of autoantibodies is another reliable indicator of immune activation.6,38 Act1 deficiency did not affect serum levels of anti-HRS IgM, IgG1, and IgG2a, though there was a modest decrease in total IgG (Fig. 5C). Loss of IκBζ did not alter total serum IgG1 or IgG2a, though there was approximately 50% impairment in IgM production in these mice (Fig. 5C). IL-17 and IκBζ are not required to drive inflammation in HRS-induced myositis. (A) Workflow of Nfkbiz conditional deletion by TAM in the HRS-induced myositis model. (B) Shown are images of paraaortic LNs in the indicated conditions and a bar chart of area (mm2) of LNs, determined by ImageJ software. Each symbol is representative of 1 sample with 2 LNs averaged. (C) Serum anti-HRS isotypes determined by ELISA. (D) Expression of mRNAs encoding cytokines, chemokines, and immune signals in muscle tissue analyzed by qPCR, normalized to Gapdh. (E) Histopathology of murine hamstring section in HRS-induced myositis stained with H&E. Arrow points to the myofiber nucleus; blue arrow, endomysial infiltration; red arrow, perimysial infiltration. Scale bar: 200 μm. Right: (F) Severity of muscle inflammation and cellular infiltration was assessed by histopathologic scoring on a scale of 0 to 39 using data pooled from 2 independent experiments. (B–D, F) Data are reported as mean ± SEM and were analyzed by 1-way ANOVA with Tukey’s test for multiple comparisons. *P < 0.05, **P < 0.01, ****P < 0.0001. As expected, Nfkbiz levels were upregulated in disease and absent in NfkbizR26ERT mice treated with TAM, indicating efficient gene deletion (Fig. 5D). Surprisingly, however, Nfkbiz transcript levels were not reduced in Act1-deficient muscle (Fig. 5D). Of the other IL-17– and IκBζ–driven genes examined, only Lcn2 was reduced in mice lacking Nfkbiz. Surprisingly, Il6, Ccl2, and Cxcl1 levels were not statistically altered by Act1 or IκBζ deficiency, though they exhibited considerable variability and chemokine expression trended downward (Fig. 5D). Thus, even though IκBζ drives transcription of IL-17–induced target genes in mesenchymal cell types, these genes are evidently controlled in response to non-Act1/IL-17–driven signals in the context of HRS-induced myositis. Severity of myositis in this mouse model system is based on the intensity and distribution of inflammatory cell infiltration and is quantified using a histopathology score ranging from 0 (absence of muscle inflammation) to 3 (severe, widespread infiltration of CD45+ inflammatory cells consisting predominantly of T cells and macrophages).6,9NfkbizR26ERT and Act1−/− mice demonstrated comparable levels of muscle inflammation to WT animals, with no apparent differences in the composition, severity, or distribution of inflammatory infiltrates (Fig. 5E, and Fig. S5). Based on these findings, we conclude that both IL-17/Act1 signaling and IκBζ are dispensable for development of HRS-induced myositis, despite the marked induction of IL-17 and IκBζ pathway genes in this system. Discussion IIMs are systemic autoimmune disorders characterized by muscle inflammation and multiorgan involvement, but the underlying molecular mechanisms responsible for disease remain poorly understood.56–58 IL-17 provokes pathology in a variety of autoimmune settings and is a strong activator of inflammatory signaling in mesenchymal cell types, including cells of the muscle.59,60 While there is prior evidence for activated IL-17 signaling in human myositis and murine model systems of this condition,15,35,37,61 direct causation has not been determined. IL-17 activates several transcriptional activators to mediate target gene expression, such as classical NF-κB, C/EBPβ, and C/EBPδ.25,62–64 However, among the genes most prominently induced in murine myositis was Nfkbiz, encoding IκBζ, a noncanonical NF-κB coactivator implicated in IL-17–mediated pathology in multiple autoimmune diseases. Nfkbiz, but not Cebpb or Cebpd, was upregulated in transcriptomic profiles of myositis, so we focused on this factor. We confirmed that IκBζ is inducible by IL-17 in primary muscle fibroblasts, resulting in enhanced expression of canonical IL-17 signature genes such as Lcn2, Il6, and Ccl2. Surprisingly, despite the evidence of IL-17 and IκBζ signals in this setting, neither Act1 nor IκBζ was required for inflammatory pathology in these studies. These observations provide insights into the interaction of different components of immune signaling in HRS-induced myositis, including those that are dispensable for inflammatory pathology. Importantly, however, these results do not prove that IL-17–mediated signals are completely irrelevant in this model of disease; rather, they suggest a degree of redundancy in signaling mediators or pathways contributing to tissue pathology in HRS-induced myositis. Consistent with this idea, Nfkbiz knockdown only partially blunted expression of many inflammatory genes that are associated with cell types implicated in disease pathogenesis, including the monocyte-recruiting chemokine Ccl2 (encoding CCL2, also known as MCP-1). A redundant regulatory network may point to other coregulators that compensate for the loss of IκBζ in the context of muscle inflammation. Additionally, recombinant HRS induced IκBζ in target cells, possibly accounting for its expression in myositis. To determine other pathways that might be compensating for or serving in place of IκBζ, we ascertained gene expression profiles in NfkbizR26ERT and Act1−/−mice and noted striking enhancement of genes in the MAPK signaling pathway, particularly Mapk3 and Mapk7. These findings suggest the MAPK signaling axis represents a promising alternative or compensatory pathway that warrants further investigation to fully elucidate its role in the pathogenesis of myositis and ASyS. Act1 is the central adaptor for IL-17R–family signaling, and nearly all studies show that Act1−/− mice lack detectable IL-17R–dependent signals and are resistant to autoimmune disease in many murine models.19 During HRS-induced myositis, Act1−/− mice showed marked impairment of known IL-17 target genes, confirming that at least these signals are not redundantly activated in the absence of IL-17–driven signals.65–67 Murine myositis is largely TLR dependent, because expression of the myositis phenotype requires the common IL-1R/TLR adaptor MyD88.6 Despite the evolutionary similarity of IL-17R with TLR families,17,68 Act1 is not required for TLR signaling, and thus essential TLR signals are evidently preserved in this knockout setting.69 Muscle fibroblasts are not merely structural scaffolds; they also serve as immunomodulatory hubs capable of sensing and propagating inflammatory signals. Indeed, cell–cell communication analyses indicate a robust network involving fibroblasts, T cells, and macrophages, consistent with findings from prior studies our group has conducted.9 In these earlier studies, scRNA-seq and corresponding pathway analyses involving derivative strains of C57BL/6 mice aligned with the paradigm that muscle fibroblasts orchestrate inflammation in murine HRS-induced myositis through alterations in Ag presentation, T-cell activation and differentiation, and pro-inflammatory cytokine production.9 Coupled with additional observations demonstrating fibroblast activation in human IIM,53 these findings underscore the role for fibroblasts in orchestrating HRS-induced myositis. IL-17–IκBζ signaling in fibroblast reticular cells directs LN expansion in several murine autoimmune settings, including experimental autoimmune encephalomyelitis and colitis.23 Fibroblast reticular cell–intrinsic IL-17R signaling not only controls LN size during inflammatory insult but also germinal center expansion and Ab production,70 thus it was surprising not to see visible changes in LN size in either Act1-deficient or IκBζ-deficient mice after HRS immunization. There were modest impacts of Act1 and IκBζ loss on autoantibody production, but these were not sufficient to prevent inflammatory cell accumulation in muscle in this disease model. Anti-cytokine biologics, including those that target IL-17 or its receptor, are now widely used to treat autoimmune conditions. However, the present results suggest that targeting the Th17 or IL-17R signaling pathway is unlikely to be fruitful in treating myositis. Studies have implicated other cytokines, in particular type 2 IFN.71 Although various therapeutic agents are used to treated myositis, most involve global immunosuppression, which underscores a need for therapeutic agents targeting mechanistically relevant pathways.72,73 Type 2 interferon or MyD88-dependent signaling pathways are both implicated in HRS-induced myositis and human disease,9,74 which would not be blocked in the setting of IL-17 blockade, possibly suggesting that combination therapy will ultimately be required to combat disease. The preclinical model of HRS-induced myositis used here can serve as a valuable tool to interrogate mechanistically relevant disease pathways and test such therapeutic strategies. Supplementary Material